Medical Device Distribution and Import into China: Orientation

Common go-to-market models

• Exclusive national distributor — fast reach; control and data opacity risks
• Regional multi-distributor — coverage; channel conflict management
• WFOE / JV as MAH-related operator or importer interface — more control; capital and licence work
• Tenders via local partners — hospital procurement rules; anti-bribery diligence

Roles that must be crystal clear

• Who holds China registration/filing for the device
• Who is importer of record and quality release owner
• Who may advertise and train KOLs · advertising guide
• Who handles adverse events and recalls
• Who owns customer and hospital data under PIPL

Ambiguity here creates both regulatory and product-liability exposure · product liability lawyers.

Distribution contract must-haves

• Territory, exclusivity, and performance minimums
• Registration ownership and cooperation on renewals/variations
• Quality agreement annex (storage, transport, traceability)
• Advertising pre-approval rights for the manufacturer
• Anti-bribery / anti-corruption and audit rights
• Pharmacovigilance / MDR reporting timelines
• Termination assistance: stock, registrations, data handback
• IP and trademark use limits

Import & quality interfaces

• Customs classification and inspection coordination
• Cold chain and UDI/traceability where applicable
• Sample management and demonstration units
• Serialisation / anti-counterfeit packaging

Manufacturer diligence checklist

• [ ] China registration strategy owner named
• [ ] Distributor licence and quality system diligence complete
• [ ] Quality agreement and PV procedures signed
• [ ] Advertising approval workflow live
• [ ] Hospital tender / compliance training for partner staff
• [ ] Data processing terms for CRM and service logs
• [ ] Exit plan if distributor underperforms

Counsel

Healthcare hub   Clinical data cross-border   Find counsel